

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

of

Application Number

Filing Date

First Named Inventor

Art Unit

Examiner Name

Thomas N. THOMAS

Attorney Docket Number

Sheet	1	of	1	Attorney Docket Number
-------	---	----	---	------------------------

## U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/D.J./		US- 6,432,991	08-13-2002	Thomas, TN	Pages 1-13
		US- 6,635,667	10-21-2003	Thomas, TN	Pages 1-13
		US- 6,482,846	11-19-2002	Garvey D.S., et al	Pages 1-33
		US- 6,593,347	07-15-2003	Bandarage UK, et al.	pages 1-15
		US- 6,544,556	04-08-2003	Chen C.M., et al	pages 1-14
		US- 6,613,784	09-02-2003	Benedini F., et al	Pages 1-10
		US- 6,649,629	11-18-2003	Bandarage UK, et al	pages 1-40
		US-			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO				Complete If Known	
				Application Number	
				Filing Date	Thomas N. Thomas
				First Named Inventor	
				Art Unit	
				Examiner Name	
Sheet 1 of 1		Attorney Docket Number			

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
/D.J./	1	Lauer MS. Aspirin for primary prevention of coronary events. <i>N Engl J Med</i> , 346: 1468-1474, 2002.			✓
	2	Fennerty BM. NSAID-related gastrointestinal injury. <i>Postgraduate Medicine</i> , 110: 87-94, 2001.			✓
	3	Yeomans ND. Approaches to healing and prophylaxis of nonsteroidal antiinflammatory Drug-associated ulcers. <i>Am. J. Medicine</i> . 110/1A: 24S - 28S, 2001			✓
	4	Glavin GB, et al. L-deprenyl attenuates stress ulcer formation in rats. <i>Neurosci. Letters</i> . 70: 379-381 (1986).			✓
	5	ThyagaRajan S. Anti-tumor effect of l-deprenyl ---in rats with carcinogen-induced Mammary tumors. <i>J. Neuroimmunol</i> . 109: 95-104, 2000.			✓
	6	Thomas, T; et al. L-Deprenyl: nitric oxide productionand dilation of cerebral blood vessels. <i>NeuroReport</i> , 9:1-6, 1998			✓
	7	Thomas, T. Monoamine oxidase-B inhibitors in the treatment of Alzheimer's disease. <i>Neurobiol. Aging</i> . 21:343-348, 2000.			✓
	8	Thomas T,et al. Aspirin and diabetes: inhibition of amylin aggregation by nonsteroidal Antiinflammatory drugs. <i>Exp Clin Endocrinol Diabetes</i> . 111: 8-11, 2003.			✓
	9	Thomas, T. et al. Inhibition of LDL oxidation by the neuroprotective drug l-deprenyl. <i>Neurol. Res</i> . 24:169-173, 2002			✓
/D.J./	10	Wallace JL and Soldato DL. The therapeutic potential of NO-NSAIDS. <i>Fundamental &amp; Clin Pharmacol</i> . 17: 11-20, 2003.			✓

Examiner Signature	/Donna Jagoe/	Date Considered	12/28/2007
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.